– Bloomberg
Piper Sandler Maintains Neutral on Vertex Pharmaceuticals, Raises Price Target to $296
Piper Sandler analyst Do Kim maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Neutral and raises the price target from $293 to $296.
Related Posts
Tesla Dangles Free Fremont Factory Tour For Chinese Customers Amid Simmering Sino-US EV Trade Tensions
The Fremont factory tour giveaway seems to be part of Tesla's broader efforts to ramp up sales in China.
PG&E Nears Deal To Sell Stake To KKR
Pacific Gas & Electric is reportedly nearing a deal to sell a stake in its fleet of power plants to KKR & Co. in an effort to raise funds needed to upgrade infrastructure and reduce the risk of fire resulting from its power lines.
Raymond James Maintains Outperform on Holley, Lowers Price Target to $3
Raymond James analyst Joseph Altobello maintains Holley (NYSE:HLLY) with a Outperform and lowers the price target from $5 to $3.